Corporate ActionApr 30, 2026, 08:15 AM
ITGR Board Initiates Strategic Review; Q1 Sales $440M, EPS $0.48
AI Summary
Integer Holdings Corp's Board of Directors has initiated a strategic review to maximize stockholder value, considering options like a sale, merger, or strategic business combination. This decision follows strong interest received in the company. Concurrently, Integer reported its first quarter 2026 results, with sales increasing 0.5% to $440 million and GAAP diluted EPS from continuing operations rising 173% to $0.48. The company also updated its 2026 outlook, expecting a return to 200 basis points above-market organic sales growth in 2027.
Key Highlights
- Board initiated a strategic review to maximize stockholder value, considering sale, merger, or business combination.
- Q1 2026 Sales increased 0.5% to $440 million, with organic growth of 1.3%.
- Q1 2026 GAAP diluted EPS from continuing operations increased 173% to $0.48.
- Q1 2026 GAAP operating income from continuing operations decreased 36% to $32 million.
- Q1 2026 Non-GAAP adjusted EBITDA decreased 7% to $85 million.
- Cardio & Vascular sales increased 1% to $262 million in Q1 2026.
- Cardiac Rhythm Management & Neuromodulation sales increased 5% to $168 million in Q1 2026.
- Updated 2026 outlook: Sales $1,805M-$1,835M; Adjusted EPS $5.83-$6.40.